Table 3 Clinical trials targeting mitophagy and mitochondrial function
From: The mitophagy pathway and its implications in human diseases
Intervention/treatment | Disease | Phase | Status and results | Trial identifier |
|---|---|---|---|---|
Urolithin A | Immune health | Not applicable | Recruiting | NCT05735886 |
Synthroid | Non-alcoholic fatty liver disease | Phase 2 | Not yet recruiting | NCT05526144 |
Other: Strength training Protein supplementation | Skeletal muscle aging | Not applicable | Completed | NCT03326648 |
Mitopure | Skeletal muscle aging | Not applicable | Completed | NCT03283462 |
Resveratrol | Skeletal muscle diseases | Early phase 1 | Recruiting | NCT04449198 |
Resveratrol | Skeletal muscle disease | Not applicable | Completed | NCT03728777 |
Resveratrol | Aging | Phase 2 | Completed | NCT02123121 |
Resveratrol | Chronic obstructive pulmonary disease | Not applicable | Completed | NCT02245932 |
Salbutamol | Insulin resistance | Not applicable | Completed | NCT04558190 |
Metformin | Metabolic diseases | Phase 4 | Completed | NCT01813929 |
Tetrahydrocannabinol Cannabidiol | Huntington’s disease | Phase 2 | Completed | NCT01502046 |
Triheptanoin | Amyotrophic lateral sclerosis | Phase 1 Phase 2 | Completed | NCT03506425 |
Lcatibant | Kidney disease | Phase 2 | Completed | NCT03177798 |
Bevacizumab | Breast cancer | Early phase 1 | Completed | NCT02806817 |
